natgillin/translations-raw huggingface dataset:
Given that the injection site is the withdrawal period determining tissue, extrapolation of residue data from products containing propylene glycol to that containing polyethylene glycol 400 cannot be justified.
Glede na to, da je tkivo, ki določa karenco, mesto injiciranja, ekstrapolacije podatkov o ostankih z zdravil, ki vsebujejo propilenglikol, na zdravila, ki vsebujejo polietilenglikol 400, ni mogoče upravičiti.
While minor differences on concentrations of the same excipients have been considered not to have an impact on residue depletion from the injection site, different solvents can have an effect on the viscosity of the formulations, and consequently affect absorption of residues from the injection site.
Čeprav velja, da manjše razlike v koncentracijah istih pomožnih snovi ne vplivajo na izločanje ostankov z mesta injiciranja, lahko različni vehikli vplivajo na viskoznost formulacij, to pa lahko posledično vpliva na absorpcijo ostankov z mesta injiciranja.
For these 49 products, excipients listed are benzyl alcohol and propylene glycol (in concentrations that differ slightly between products), as well as small concentrations of different pH adjustors.
Za teh 49 zdravil so kot pomožne snovi navedeni benzilalkohol in propilenglikol (v koncentracijah, ki se med zdravili nekoliko razlikujejo) ter različni regulatorji pH v majhnih koncentracijah.
It has been noted that there are different approved withdrawal periods for sheep (milk, meat and offal) for veterinary medicinal products containing tylosin presented as solution for injection to be administered to sheep across the EU, e.g. sheep meat and offal from 8 days to 42 days; sheep milk from 4 days to 7 days.
Ugotovljeno je bilo, da obstajajo za zdravila za uporabo v veterinarski medicini, ki vsebujejo tilozin v obliki raztopine za injiciranje za ovce, v EU različne karence za ovce (mleko, meso in organi), na primer od 8 dni do 42 dni za meso in organe ovac ter od 4 dni do 7 dni za mleko ovac.
In absence of residue depletion data in the major species sheep, the Netherlands considered that the withdrawal period for sheep of the reference product (Tylan 200) has not been adequately justified.
V odsotnosti podatkov o izločanju ostankov pri glavni vrsti ovce je Nizozemska menila, da karenca pri ovcah za referenčno zdravilo (zdravilo Tylan 200) ni bila zadostno utemeljena, zato je ustreznost karence za referenčno zdravilo pri ovcah nezanesljiva.
The application of the generic product (Tylovectin) concerned cattle, pigs, sheep and goats as the target species, which is in line with the reference product as authorised in France (Tylan 200).
Uporaba generičnega zdravila (zdravila Tylovectin) se je nanašala na govedo, prašiče, ovce in koze kot ciljne vrste, kar je v skladu z referenčnim zdravilom, odobrenim v Franciji (zdravilo Tylan 200), vendar v nekaterih državah članicah, vključno z Nizozemsko, referenčno zdravilo ni bilo odobreno za uporabo pri ovcah.
Data from this study could not be used as a basis for extrapolating the withdrawal period for the only product containing the excipient polyethylene glycol 400 (Tilocen, marketing authorisation holder: A. Nikolakopoulos S.A), as differences between the absorption of residues from the injection site for these two products (i.e., given the differences on viscosities from products with different excipients) cannot be excluded, as mentioned in the section above.
Podatkov iz te študije ni bilo mogoče uporabiti kot podlago za ekstrapolacijo karence na edino zdravilo, ki kot pomožno snov vsebuje polietilenglikol 400 (zdravilo Tilocen, imetnik dovoljenja za promet z zdravilom: A. Nikolakopoulos, S.A), saj ni mogoče izključiti razlik med absorpcijo ostankov z mesta injiciranja teh dveh zdravil (tj. glede na razlike v viskoznosti zdravil z različnimi pomožnimi snovmi), kot je navedeno v predhodnem odstavku.
For these 49 products, excipients listed are benzyl alcohol and propylene glycol, as well as small concentrations of different pH adjustors.
Za teh 49 zdravil so kot pomožne snovi navedeni benzilalkohol in propilenglikol ter različni regulatorji pH v majhnih koncentracijah.
For the product Tilocen (marketing authorisation holder: A. Nikolakopoulos S.A) containing tylosin presented as solution for injection for use in target species sheep, and containing polyethylene glycol 400, there was no data available that could be used to determine adequate withdrawal periods that could assure that after 42 days after treatment, the residues are below the established MRLs for tylosin in sheep.
Za zdravilo Tilocen (imetnik dovoljenja za promet z zdravilom: A. Nikolakopoulos, S.A), ki vsebuje tilozin v obliki raztopine za injiciranje za uporabo pri ciljnih vrstah ovce in polietilenglikol 400, ni bilo podatkov, ki bi jih lahko uporabili za določitev ustreznih karenc, ki bi zagotovile, da so po 42 dneh po zdravljenju ostanki pod določenimi MRL za tilozin pri ovcah.
An additional safety factor of 30% was considered necessary in view of the limited number of animals treated (n=3), their weight (12 kg mean bw) and consequently the small injection volume required to treat these three lambs (0.6 ml), together with the lack of analysis of injection site ring samples, resulting in a withdrawal period of 28 days.
Zaradi omejenega števila zdravljenih živali (n = 3), njihove telesne mase (povprečna telesna masa 12 kg) in posledično majhnega volumna injiciranja, potrebnega za zdravljenje teh treh jagnjet (0,6 ml), skupaj s pomanjkanjem analize vzorcev obročev na mestu injiciranja, je bil potreben dodaten 30-odstotni varnostni faktor, kar je privedlo do 28-dnevne karence.
The differences in concentrations of benzyl alcohol and propylene glycol, and in pH adjustors, have also been considered not to have an impact on residue absorption from tissues and the injection site.
Za razlike v koncentracijah benzilalkohola in propilenglikola ter regulatorjev pH ni veljalo, da vplivajo na absorpcijo ostankov iz tkiv in z mesta injiciranja.
At day 21 after the last dose was administered, the residue concentrations in all samples of the injection site were below the established maximum residue limit (MRL) for tylosin in sheep meat of 100 µg/kg.
21. dan po dajanju zadnjega odmerka so bile koncentracije ostankov v vseh vzorcih na mestu injiciranja pod mejno vrednostjo ostankov (MRL), določeno za tilozin v mesu ovac, ki znaša 100 µg/kg.
• a GLP compliant residue study conducted with tylosin solution for injection, used intramuscularly in sheep was provided, and from which withdrawal periods could be established for meat and offal of treated sheep for 49 concerned products, i.e., those with excipients benzyl alcohol and propylene glycol.
• Predložena je bila z dobro laboratorijsko prakso skladna študija ostankov, izvedena z raztopino tilozina, ki se uporablja intramuskularno pri ovcah, na podlagi katere je bilo mogoče določiti karence za meso in organe zdravljenih ovac za 49 zadevnih zdravil, tj. tiste s pomožnima snovema benzilalkoholom in propilenglikolom.
• on the basis of the available data, the CVMP considered the withdrawal periods for meat and offal, and milk derived from treated sheep cannot be established for Tilocen (marketing authorisation holder: A. Nikolakopoulos S.A), as referred in Annex I.
• Na podlagi razpoložljivih podatkov je odbor CVMP presodil, da karenc za meso, organe in mleko, pridobljene iz zdravljenih ovac, za zdravilo Tilocen (imetnik dovoljenja za promet z zdravilom: A. Nikolakopoulos, S.A), kot je navedeno v Prilogi I, ni mogoče določiti.
For one product (Tilocen), the solvent polyethylene glycol 400 was used instead of propylene glycol.
Za eno zdravilo (zdravilo Tilocen) je bil namesto propilenglikola uporabljen vehikel polietilenglikol 400.
Given that the viscosities of propylene glycol and polyethylene glycol 400 are different, a significant impact on the absorption and residue depletion, and consequently on the withdrawal periods needed for tylosin solutions for injections with these different excipients cannot be excluded.
Glede na to, da se viskoznosti propilenglikola in polietilenglikola 400 razlikujeta, ni mogoče izključiti njunega pomembnega vpliva na absorpcijo in izločanje ostankov ter posledično na karence, potrebne za raztopine tilozina za injiciranje, ki vsebujejo te različne pomožne snovi.
Tylosin residues were detected in milk during the treatment, and were below the established MRL for tylosin in cattle milk (50 µg/kg) 36 hours after the last administration, and were not detected 48 hours after the last treatment dose.
Med zdravljenjem so bili v mleku zaznani ostanki tilozina, katerih raven je bila 36 ur po zadnjem dajanju nižja od določenega MRL za tilozin v mleku goveda (50 µg/kg), 48 ur po zadnjem odmerku zdravljenja pa jih ni bilo več mogoče zaznati.
Therefore, the Committee considers that the benefit-risk balance for the veterinary medicinal product Tilocen (marketing authorisation holder: A. Nikolakopoulos S.A) containing tylosin presented as solution for injection for use in target species sheep, and containing polyethylene glycol 400 is not favourable in the absence of adequate residue depletion data in sheep to justify a withdrawal period of 42 days for sheep meat and offal, and 108 hours for sheep milk.
Odbor zato meni, da razmerje med koristmi in tveganji za zdravilo za uporabo v veterinarski medicini Tilocen (imetnik dovoljenja za promet z zdravilom: A. Nikolakopoulos, S.A), ki vsebuje tilozin v obliki raztopine za injiciranje za uporabo pri ciljni vrsti ovce in polietilenglikol 400, zaradi pomanjkanja podatkov o izločanju ostankov pri ovcah, ki bi upravičili 42-dnevno karenco za meso in organe ovac ter 108-urno karenco za mleko ovac, ni ugodno.
Consequently, the CVMP is proposing to harmonise the milk withdrawal period to products concerned to 108 hours following the approached outlined in the guideline mentioned above.
Odbor CVMP zato predlaga, da se na način, opisan v zgoraj omenjenih smernicah, karenca za mleko poenoti s karenco zadevnih zdravil na 108 ur.
It is noted that a withdrawal period of 42 days for meat and offal is currently established for several of the products within this referral procedure.
Ugotovljeno je, da je pri več zdravilih v okviru tega napotitvenega postopka trenutno določena 42dnevna karenca za meso in organe.
Having considered the grounds for referral and the data available, the CVMP concluded that for 49 out of 50 products, these being all those containing benzyl alcohol and propylene glycol as excipients, the withdrawal periods for meat and offal derived from treated sheep should be amended to 42 days, and the withdrawal periods for milk derived from treated sheep should be amended to 108 hours to provide assurance for consumer safety.
Odbor CVMP je po preučitvi razlogov za napotitev in razpoložljivih podatkov sklenil, da je treba za zagotovitev varnosti potrošnikov za 49 od 50 zdravil, pri čemer so to vsa tista, ki kot pomožni snovi vsebujejo benzilalkohol in propilenglikol, karenco za meso in organe, pridobljene iz zdravljenih ovac, spremeniti v 42 dni, karenco za mleko, pridobljeno iz zdravljenih ovac, pa je treba spremeniti v 108 ur.
Data from the literature indicated that the residue depletion from milk from sheep is faster than from milk from cows.
Podatki iz literature kažejo, da se ostanki iz mleka ovac izločajo hitreje kot iz mleka krav.
On the basis of a proprietary residue depletion study in sheep tissues, a withdrawal period for sheep meat and offal of 42 days could be derived for 49 concerned products.
Na podlagi lastniške študije o izločanju ostankov iz tkiv ovac je bilo za 49 zadevnih zdravil mogoče za meso in organe ovac določiti 42-dnevno karenco.
This withdrawal period was considered adequate and safe for the consumer as far as the injection volume was restricted.
Ta karenca se je ob omejenem volumnu injiciranja štela za primerno in varno za potrošnika.
The other submitted study was a GLP-compliant residue study with tylosin solution for injection, conducted in sheep via intramuscular administration.
Druga predložena študija je bila študija o ostankih, skladna z dobro laboratorijsko prakso, ki je bila izvedena pri ovcah z raztopino tilozina za injiciranje, in sicer z intramuskularnim dajanjem.
5 CVMP note for guidance on the approach towards harmonisation of withdrawal periods (EMEA/CVMP/036/95) - link the influence of increasing the injection volume/site of injection on the absorption rate is difficult to quantify.
5 CVMP note for guidance on the approach towards harmonisation of withdrawal periods (EMEA/CVMP/036/95) - link za več kot 250 %.
However, as the injection site is the withdrawal period determining tissue, for the product containing polyethylene glycol 400 (Tilocen, marketing authorisation holder: A. Nikolakopoulos S.A), and in view of the effect of this excipient on product viscosity, a different rate of absorption of residues from the injection site cannot be ruled out.
Ker pa je tkivo, ki določa trajanje karence, mesto injiciranja, za zdravilo, ki vsebuje polietilenglikol 400 (zdravilo Tilocen, imetnik dovoljenja za promet z zdravilom: A. Nikolakopoulos, S.A), in glede na učinek te pomožne snovi na viskoznost zdravila ni mogoče izključiti drugačne hitrosti absorpcije ostankov z mesta injiciranja.
1 CVMP guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market (EMA/CVMP/SWP/66781/2005-Rev.1)https://www.ema.europa.eu/documents/scientific-guideline/guideline-safety-residue-data-requirements-pharmaceuticalveterinary-medicinal-products-intended/limited-market_en.pdf the CVMP in the interests of protecting consumer safety in the Union, and requested the Committee to review all available residue depletion data and recommend withdrawal periods for sheep (meat and offal, and milk).
1 CVMP guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market (EMA/CVMP/SWP/66781/2005-Rev.1)https://www.ema.europa.eu/documents/scientific-guideline/guideline-safety-residue-data-requirements-pharmaceuticalveterinary-medicinal-products-intended/limited-market_en.pdf uporabo v veterinarski medicini (CVMP), ter zahtevala, da Odbor pregleda vse razpoložljive podatke o izločanju ostankov in priporoči karence pri ovcah (za meso, organe in mleko).
At day 21 after the last dose was administered, the residue concentrations in the injection site were all below the established MRL for tylosin in sheep meat, of 100 µg/kg.
21. dan po dajanju zadnjega odmerka so bile vse koncentracije ostankov na mestu injiciranja pod mejno vrednostjo ostankov za tilozin v mesu ovac, ki znaša 100 µg/kg.
A GLP compliant residue depletion study was provided by one of the marketing authorisation holders involved in the procedure, and while a number of shortcoming on the study design were identified, the data allowed the recommendation to have a 42 day withdrawal period for meat and offal for 49 out of the 50 concerned products, i.e., for products containing 50 mg/ml and 200 mg/ml tylosin as a solution for injection for intramuscular use in sheep, containing benzyl alcohol and propylene glycol as excipients.
Čeprav so bile pri pregledu načrta študije ugotovljene številne pomanjkljivosti, so podatki omogočili določitev 42-dnevne karence za meso in organe za 49 od 50 zadevnih zdravil, tj. za zdravila, ki vsebujejo 50 mg/ml in 200 mg/ml tilozina v obliki raztopine za injiciranje za intramuskularno uporabo pri ovcah, ki kot pomožni snovi vsebujejo benzilalkohol in propilenglikol.
Cattle,
ovce
The remaining product contains polyethylene glycol 400 instead of propylene glycol.
Preostalo zdravilo namesto propilenglikola vsebuje polietilenglikol 400.
Given that the viscosities of propylene glycol and polyethylene glycol 400 are different, a significant impact on the absorption and residue depletion from the injections site, and consequently on the withdrawal periods cannot be excluded.
Glede na to, da sta viskoznosti propilenglikola in polietilenglikola 400 različni, ni mogoče izključiti pomembnega vpliva na absorpcijo in izločanje ostankov z mesta injiciranja ter posledično na karence.
DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION For sheep over 50 kg of bodyweight, the injection should be divided over two injection sites (maximum 2.5 ml injection volume per injection site).
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA Pri ovcah s telesno maso več kot 50 kg je treba injiciranje razdeliti na dve mesti injiciranja (največ 2,5 ml volumna injiciranja na mesto injiciranja).
BOVINS OVINS CAPRINS ET PORCINS
CAPRINS ET PORCINS
All references to target species sheep should be deleted from the summary of product characteristics, labelling and package leaflet.
Iz povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo je treba izbrisati vse navedbe za ciljno vrsto ovce.
Nevertheless, it has been reported that the rate of absorption from the injection site depends on a number of factors (e.g. injection volume, excipients, lipophilicity of the active substance), and without specific residue data,
Kljub temu so poročali, da je hitrost absorpcije na mestu injiciranja odvisna od številnih dejavnikov (npr. volumna injiciranja, pomožnih snovi, lipofilnosti učinkovine), zato je brez specifičnih podatkov o ostankih težko izmeriti vpliv povečanja volumna injiciranja/mesta injiciranja na hitrost absorpcije.
No proprietary residue depletion studies in ewes were submitted.
Predložena ni bila nobena lastniška študija o izločanju ostankov pri ovčjih samicah.
Although a number of shortcoming were identified from this study (more specifically that the number of treated animals (n=3) was below the number required in VICH GL 48, animals were very young (12 kg mean bw), and also the sampling of the injection site did not include an outer ring sample), the results showed that the injection site is the withdrawal period determining tissue and results from this residue study have been used for establishing the withdrawal periods for 49 out of the 50 products concerned.
Zato podatkov iz te študije, iz zgoraj navedenega razloga, ni bilo mogoče ekstrapolirati na edino zdravilo, ki vsebuje pomožno snov polietilenglikol 400 (zdravilo Tilocen, imetnik dovoljenja za promet z zdravilom: A. Nikolakopoulos, S.A) Čeprav so bile v tej študiji ugotovljene številne pomanjkljivosti (natančneje, število zdravljenih živali (n = 3) je bilo manjše od števila, zahtevanega v smernicah VICH GL 48, živali so bile zelo mlade (povprečna telesna masa 12 kg), poleg tega pa vzorčenje na mestu injiciranja ni vključevalo vzorca zunanjega obroča), so rezultati pokazali, da je tkivo, ki določa karenco, mesto injiciranja, rezultati iz te študije ostankov pa so bili uporabljeni za določitev karence za 49 od 50 zadevnih zdravil.
The CVMP guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market (EMA/CVMP/SWP/66781/2005-Rev.1)1 allows extrapolation of the withdrawal period between animal species, but only from a major species to a minor species.
Smernice odbora CVMP o zahtevah glede podatkov o varnosti in ostankih za zdravila za uporabo v veterinarski medicini, namenjena za manj pomembno uporabo ali uporabo pri manj pomembnih vrstah (MUMS)/na omejenem trgu (EMA/CVMP/SWP/66781/2005-Rev.1)1, omogočajo ekstrapolacijo karence med živalskimi vrstami, vendar le z glavne vrste na manj pomembno vrsto.
For the product containing the excipient polyethylene glycol 400 (Tilocen, marketing authorisation holder: A. Nikolakopoulos S.A), no suitable residue depletion data are available for establishing a withdrawal period for sheep meat, offal, and milk.
Za zdravilo, ki vsebuje pomožno snov polietilenglikol 400 (zdravilo Tilocen, imetnik dovoljenja za promet z zdravilom: A. Nikolakopoulos, S.A), ni na voljo ustreznih podatkov o izločanju ostankov za določitev karence za meso, organe in mleko ovac.
Residue depletion in sheep meat and offal
Izločanje ostankov iz mesa in organov ovac
Therefore the Committee used the ‘alternative' method for determining the withdrawal period, in line with CVMP note for guidance on the approach towards harmonisation of withdrawal periods (EMEA/CVMP/036/95)5.
Zato je Odbor v skladu z usmerjevalno opombo odbora CVMP o pristopu k usklajevanju karenc (EMEA/CVMP/036/95)5 za določanje karence uporabil „alternativno“ metodo.
Tylosin tartrate
Tylmasin tilozinijev tartrat
For sheep over 50 kg, however, the CVMP recommends that the dose is divided over two injection sites (maximum injection volume per site of 2.5 ml).
Odbor CVMP za ovce, težje od 50 kg, priporoča, da se odmerek razdeli na dve mesti injiciranja (največji volumen injiciranja 2,5 ml na mesto).
The differences on concentrations of benzyl alcohol and propylene glycol, and on pH adjustors have been considered not to have an impact on residue absorption from the injection site.
Odbor je presodil, da razlike v koncentracijah benzilalkohola in propilenglikola ter regulatorjev pH ne vplivajo na absorpcijo ostankov z mesta injiciranja.
PHARMASIN 50 mg/ml injekcinis tirpalas kiaulėms, galvijams, avims, ožkoms, šunims ir katėms
PHARMASIN 50 mg/ml injekcinis tirpalas kiaulėms, galvijams, avims, ožkoms, šunims ir katėms mačke, govedo, psi, koze, prašiči, ovce
A half-life (T1/2) of approximately two days for the absorption from the injection site was determined from the available residue study.
To pomeni, da se na mestu injiciranja odloži približno štirikrat večja količina tilozina, kot je bila uporabljena v razpoložljivi študiji ostankov, z volumnom 0,6 ml. Razpolovna doba (T1/2) približno 2 dni za absorpcijo z mesta injiciranja je bila določena na podlagi razpoložljive študije o ostankih.
Tylovet B-50, solution for injection for cattle, sheep, goats, swine, dogs and cats
Tylovet B-50, solution for injection for cattle, sheep, goats, swine, dogs and cats mačke, govedo, psi, koze, prašiči, ovce
Tylovet B-200 solution for injection for cattle, sheep, goats, swine and dogs
Tylovet B-200 solution for injection for cattle, sheep, goats, swine and dogs govedo, psi, koze, prašiči, ovce
While the residue studies mentioned above were made available, milk from sheep is considered a minor food commodity, and withdrawal periods for sheep milk can be extrapolated from those for cows' milk in accordance with the CVMP guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market (EMA/CVMP/SWP/66781/2005-Rev.1).
Čeprav so bile zgoraj navedene študije o ostankih na voljo, se mleko ovac šteje za manj pomembno živilo in se lahko karenca zanj v skladu s smernicami odbora CVMP o zahtevah glede varnosti in podatkov o ostankih za zdravila za uporabo v veterinarski medicini, namenjena za manj pomembno uporabo ali uporabo pri manj pomembnih vrstah (MUMS)/na omejenem trgu (EMA/CVMP/SWP/66781/2005-Rev. 1), ekstrapolira s karenc za kravje mleko.
Regarding the establishment of withdrawal periods for sheep milk, no proprietary residue depletion studies in ewes were submitted.
V zvezi z določitvijo karence za ovčje mleko niso bile predložene nobene lastniške študije o izločanju ostankov pri ovčjih samicah, odboru CVMP pa sta bili predloženi dve javno9, 10 dostopni študiji.
A GLP-compliant residue study with tylosin solution for injection, conducted in sheep via intramuscular administration was made available to CVMP.
Odbor CVMP je dal na razpolago študijo o ostankih, skladno z dobro laboratorijsko prakso, ki je bila izvedena pri ovcah z raztopino tilozina za injiciranje, in sicer z intramuskularnim dajanjem.
2600 Antwerpen Belgium bovini, ovini, caprini e suini route
Uitbreidingstraat 80 2600 Antwerpen Belgium soluzione iniettabile per bovini, ovini, caprini e suini baza injiciranje koze, prašiči, ovce intramuskularna pot
MG/ML SOLUTION INJECTABLE POUR
MG/ML SOLUTION INJECTABLE POUR BOVINS OVINS
For only one concerned product (Tilocen, marketing authorisation holder: A. Nikolakopoulos S.A), the solvent polyethylene glycol 400 is used instead of propylene glycol.
Nikolakopoulos, S.A) se namesto propilenglikola uporablja vehikel polietilenglikol 400.